Purpose of review
The field of pediatric cardiac arrest experienced recent advances secondary to multicenter collaborations. This review summarizes developments during the last year and identifies areas for further research.
Recent findings
A large retrospective review demonstrated important differences in cause, severity, and outcome of in-hospital vs. out-of-hospital pediatric cardiac arrest. This distinction is relevant to interpretation of retrospective studies that may not distinguish between these entities, and in planning therapeutic clinical trials. Hypothermia was further evaluated as a treatment strategy after neonatal hypoxia and leaders in the field of neonatology recommend universal use of hypothermia in term neonates at risk. In infants and children after cardiac arrest, there are inadequate data to make a specific recommendation. Two retrospective studies evaluating hypothermia in children after cardiac arrest found that it tended to be administered more frequently to sicker patients. However, similar or worse outcomes of patients treated with hypothermia were observed. Use of extracorporeal membrane oxygenation is another emerging area of research in pediatric cardiac arrest, and surprisingly good outcomes have been seen with this modality in some cases. Summary Therapeutic hypothermia and extracorporeal membrane oxygenation continue to be the only treatment modalities over and above conventional care for pediatric cardiac arrest. New approaches to monitoring, treatment, and rehabilitation after cardiac arrest remain to be explored. 72 h), and recovery phase (beyond 3 days). Therapy targeting each of these phases has a defined goal: interventions in the early phases focus on limiting further injury and vital support, whereas those in the later phases focus on prognostication and finally rehabilitation [5 ].
Incidence of cardiac arrest
Epidemiology and outcomes of out-of-hospital cardiac arrest were reported in a prospective cohort of 624 infants and children who received CPR between 2005 and 2007. The incidence of cardiac arrest in infants approaches that of adults (72.71 vs. 126 per 100 000 person-years) and is higher as compared with children and adolescents (3.73 and 6.37 per 100 000 person-years, respectively) [6 ] .
In-hospital vs. out-of-hospital cardiac arrest Pediatric cardiac arrest can occur out of the hospital setting (out-of-hospital cardiac arrest) or in hospital (in-hospital cardiac arrest). A retrospective review [7 ] reported prearrest characteristics, postarrest interventions, mortality, and neurological outcome after in-hospital and out-ofhospital cardiac arrest, and concluded that these represent discrete entities with respect to cause, first monitored rhythm recorded, mortality during resuscitation and in the postcardiac arrest period, and neurological outcome. The difference in outcome between in-hospital and outof-hospital cardiac arrest may simply represent a shorter duration of no flow and higher-quality CPR for patients after in-hospital than out-of-hospital cardiac arrest. Thus, when evaluating different therapies, these groups of patients should be analyzed separately as they represent different degrees of disease severity [7 ] . A comparison of in-hospital and out-of-hospital cardiac arrest from the previous reference is presented in Table 1 .
Epidemiology of postcardiac arrest syndrome: survival and neurological outcome
In a recent large prospective pediatric cohort study [6 ] , overall survival from out-of-hospital cardiac arrest was 6.4% (children 9.1%, adolescents 8.9%, and infants 3.3%). A subset analysis of patients who achieved ROSC demonstrated that those successfully resuscitated before hospital arrival had a higher rate of survival to hospital discharge as compared with patients transported in cardiac arrest (37 vs. 10%) [6 ] . Similarly, patients with ROSC after out-of-hospital cardiac arrest in another study [7 ] had a chance of survival to hospital discharge of 38%. Fifty-six percent of these patients had good neurological outcome.
Patients with in-hospital cardiac arrest have a better survival to hospital discharge as compared with patients with out-of-hospital cardiac arrest. Survival rates for inhospital cardiac arrest ranged from 16 to 38% in different studies published in the last decade [3] . Patients who achieved ROSC after in-hospital cardiac arrest had a rate of survival to discharge of 49%. Seventy-eight percent of these patients had good neurological outcome [7 ] .
Favorable neurological outcome is more often achieved in patients with in-hospital cardiac arrest as compared with out-of-hospital cardiac arrest (47 vs. 24%), in spite of patients with in-hospital cardiac arrest having a higher frequency of abnormal prearrest neurological status (34 vs. 17%) and chronic preexisting conditions (88 vs. 49%) ( Table 1) .
Mechanisms of brain damage
Asphyxia produces a state of hypoxemic hypotensive perfusion before cardiac arrest. Pediatric and neonatal models of hypoxia-ischemia and asphyxia exist, and therapies, brain tissue monitoring, cerebral blood flow, and outcomes can be studied using these models. Data related to mechanisms of brain damage from children after cardiac arrest are limited. During ischemia, energy stores of the brain are depleted, and toxic metabolites accumulate (lactate and hydrogen ion). Upon reperfusion, injury to the brain is secondary to excitotoxicity, calcium accumulation, protease activation, and formation of reactive oxygen and nitrogen species. The mechanism of neuronal damage after cardiac arrest is a combination of apoptosis, autophagy, and necrosis, along with inflammation.
Cerebral blood flow, tissue oxygenation, and biomarkers after cardiac arrest
Postresuscitation cerebral blood flow (CBF) in a pediatric model of asphyxial cardiac arrest was recently shown to be highly dependent on both duration of cardiac arrest and specific brain regions. Early after ROSC (5-15 min), hyperemia was limited to subcortical areas. Hypoperfusion of the cortex occurred after 15 min post-ROSC and was more pronounced for longer durations of cardiac arrest such as 9-12 min [8] .
In clinical work, near-infrared spectroscopy (NIRS) is a noninvasive tool that measures cortical regional oxyhemoglobin saturation as an indirect indicator of cortical brain oxygenation and CBF [9] . During cardiopulmonary bypass for congenital cardiac repairs, NIRS-derived cerebral oxygenation correlated with postoperative neurological changes [10] . To date, there are no studies reporting its use in children after cardiac arrest. A report [11] of one child monitored before and during a cardiac arrest demonstrated that the regional oxygen saturation decreased markedly during cardiac arrest and CPR, and was recovered after ROSC to levels below baseline. Cerebral NIRS might also represent a potential early warning monitor to prevent progression to cardiac arrest [12] . Electroencephalographic monitoring after cardiac arrest is helpful in detecting seizures that may not be detectable by clinical examination [13] .
Biomarkers have been studied after cardiac arrest in adults with the aim of prognosticating neurological outcome. These biomarkers include neuronal-specific enolase (NSE), S-100B, serum creatine phosphokinase isoform BB, and inflammatory markers. A review of this topic concluded that there are insufficient data supporting use of these biomarkers to predict outcome [14] , although serum biomarkers have much more utility than simply prognostication, such as therapeutic monitoring or assessment of mechanistic targets or insult severity [15] . There are limited data evaluating these biomarkers in children after cardiac arrest [16] . However, two recent studies [17, 18] show that biomarkers, particularly NSE, have great promise in pediatric cardiac arrest.
Hypothermia
A multitude of therapies resulted in neuroprotection in animal models of cardiac arrest and neonatal hypoxiaischemia; however, only hypothermia was proven to offer clinical neuroprotection in term neonates after hypoxic ischemic events [19, 20] and in adults after cardiac arrest [21, 22] . It is now universally accepted that early hypothermia, maintained for 24-72 h, at brain temperatures of 32-348C, improves neurological outcome in term neonates after hypoxia-ischemia and adults after ventricular fibrillation cardiac arrest. There are insufficient data to make specific recommendation for use of hypothermia in infants and children.
In neonates with hypoxic ischemic encephalopathy (HIE), two large randomized controlled trials (RCTs) [19, 23] published in 2005 suggested that hypothermia was associated with reduction in death and disability at 18 months after insult. Another large RCT [24] of hypothermia after HIE was completed in the UK, along with follow-up to 18 months, and data are under analysis at this time. A RCT [25 ] in the United States proved that hypothermia is well tolerated; there was also a trend in reducing death and decreasing disability at 18-22 months, but the study was not powered for this endpoint. A meta-analysis of studies [26] [27] [28] [29] published to date in the neonatal population reported a significant positive effect of hypothermia on disability and death. On the basis of this evidence, leaders in the field of neonatology recommend universal use of hypothermia in neonates with hypoxic ischemic encephalopathy [30 ] .
There is a hiatus in studies of therapeutic hypothermia in infants and children after cardiac arrest outside the neonatal period. To date, only two retrospective studies have been published, along with a few case reports. One study [31 ] , conducted by the Canadian Critical Care Trial Groups, reviewed clinical charts of patients treated after cardiac arrest in four centers in Canada and one center in the UK from 2001 to 2003. Patients treated with hypothermia had a greater severity of illness prior to initiating cooling as compared with patients maintained normothermic [duration of cardiac arrest 30 vs. 10 min, larger doses of epinephrine were required during resuscitation, greater use of extracorporeal membrane oxygenation (ECMO), and higher organ dysfunction scores on admission]. Before adjustment for the severity of illness, mortality was higher after hypothermia. After adjustment for these variables, there was no difference in mortality between groups. Another study [32] reviewed data from 181 pediatric patients treated with hypothermia (n ¼ 40) or normothermia (n ¼ 141) after cardiac arrest from 2000 to 2006 at a single center in the United States. There was no difference in mortality between the two groups. As in the previous study, patients treated with hypothermia tended to have a greater severity of illness (more unwitnessed cardiac arrest, more doses of epinephrine administered until ROSC, and greater frequency of out-ofhospital cardiac arrest) [32] . There are no prospective randomized trials published to date regarding therapeutic hypothermia in this population. There are two RCTs with active recruitment: Children's Hospital of Pittsburgh (USA) and Hospital for Sick Children (Canada) and two planned RCTs that will evaluate therapeutic hypothermia in children with out-of-hospital and in-hospital cardiac arrest (http://clinicaltrials.gov).
Given that therapeutic hypothermia in the range of 33-348C appears to be safe and potentially improves outcome, it should be considered in children with cardiac arrest. The 2005 American Heart Association guidelines recommend that therapeutic hypothermia should be considered in infants and children after cardiac arrest. However, a study [33] conducted in 2004 assessing the knowledge of pediatric ICU physicians regarding hypothermia in the setting of cardiac arrest reports that only 9% of participating physicians used hypothermia consistently in comatose children, and an additional 38% used it 'sometimes'. The hypothetical use of hypothermia was associated with the likelihood of postarrest recovery, and there was a wide variation in methodology and duration of hypothermia, originating from lack of evidence and protocols [33] . A recent report [34] on methods of cooling demonstrated that a servo-controlled fan with feedback from an esophageal temperature probe was efficacious in 10 infants cooled to 33-348C. A detailed review [35 ] of therapeutic hypothermia in children along with methods of cooling was recently published.
Finally, increased temperature after HIE or cardiac arrest is associated with poor outcome. This may represent either noxious effect of hyperthermia on the injured brain or a worse insult overall with multiorgan system failure [36] . As little as one degree of hyperthermia appears to be important.
Extracorporeal membrane oxygenation
ECMO can be used as a rescue tool for pediatric patients with cardiac arrest in whom ROSC cannot be obtained (extracorporeal cardiopulmonary resuscitation or ECPR), as a therapy for patients with extreme cardiovascular instability after ROSC, or as a tool to deliver hypothermia in one of these previous scenarios. Simply put, ECMO represents delivery of oxygenated blood in a continuous flow to the systemic circulation.
ECMO was first used for resuscitation from cardiac arrest in a dog model of cardiac arrest in the late 1980s, and shortly afterwards it was used in humans [37, 38] . From a technical standpoint, venous blood from the vena cava is directed to an oxygenator and the oxygenated blood is pumped into the aorta, providing oxygenation, CO 2 removal, and hemodynamic support. Physiological advantages and disadvantages of ECMO are reviewed in detail in a recent pediatric publication [39 ] . ECMO is an invasive therapy with the obvious benefit of possible resuscitation or survival in a patient who is unlikely to survive otherwise. Major risks include vascular injury with compromise of distal perfusion, central nervous system complications (i.e. bleeding and ischemia), myocardial stun, pulmonary hemorrhage, infections, and bleeding.
Initial reports [40, 41] of ECPR were limited to children after cardiac surgeries. In the past 5 years, three studies [42] [43] [44] presented experience related to ECPR in a variety of patients with primarily in-hospital cardiac arrest. A meta-analysis [45 ] of pediatric patients who received ECPR from 1990 to 2007 included a majority of patients (75%) with cardiac arrest in the perioperative period. The overall survival was 39.6%. Frequent complications included neurological (27%), renal (25%), and sepsis (17%). Mortality was highest in patients with neurological and renal complications and in patients with long deployment of ECMO system (more than 30 min), and was lowest in patients with cardiomyopathies and myocarditis [45 ] . A recent study [46 ] from Taiwan, which was not included in the previous meta-analysis, reports experience with 17 patients with in-hospital cardiac arrest followed by ECPR. The overall survival for patients receiving ECPR was 41%, 10 out of 11 patients (91%) with good neurological outcome. Similarly to previous studies, nonsurvivors had longer CPR duration before institution of ECMO and higher incidence of renal failure during ECMO support. This study describes in its methods the key elements of a successful ECPR sequence: education of critical care personnel about the benefits of ECPR and encouragement of early consultation, early deployment of ECMO 'if the patients did not have sustained ROSC within 10-15 min and had no obvious contraindications (the physician) proceeded to ECPR', and preparedness of ECMO team, consisting of surgeon and ECMO technician [46 ] . ECMO and hypothermia after cardiac arrest can be combined, as presented in a recent case series [47] of two pediatric patients.
Future directions
As reviewed here, there are no current accepted strategies for brain monitoring after cardiac arrest. Neurological dysfunction is the principal limiting factor in the successful recovery of pediatric patients after cardiac arrest. There appears to be a need for applying contemporary neurocritical care monitoring to patients after cardiac arrest and for goal-directed resuscitation strategies.
Conclusion
Hypothermia and ECMO are the only treatment modalities available for improving brain recovery in the postcardiac arrest syndrome. Recent advances in the field of pediatric cardiac arrest were possible because of collaborative multicenter clinical studies. Many uncharted territories remain in brain monitoring, therapy, and rehabilitation from pediatric cardiac arrest. Well planned RCTs are underway to establish the role of hypothermia as a treatment modality for pediatric cardiac arrest.
